The putative prostacyclin receptor antagonist (FCE-22176) is a full agonist on human platelets and NCB-20 cells
- 1 August 1986
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 127 (1-2) , 117-119
- https://doi.org/10.1016/0014-2999(86)90211-6
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- A stable isosterically modified prostacyclin analogue, FCE-22176, acting as a competitive antagonist to prostacyclin in guinea-pig trachea and atriaEuropean Journal of Pharmacology, 1985
- The use of a prostacyclin analogue, [3H]iloprost, for studying prostacyclin-binding sites on human platelets and neuronal hybrid cellsBioscience Reports, 1984
- Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects.British Journal of Clinical Pharmacology, 1983
- Selective Binding Site for [3H]Prostacyclin on PlateletsJournal of Clinical Investigation, 1979
- Pulmonary and systemic vasodilator effects of the newly discovered prostaglandin, PGI2Journal of Applied Physiology, 1978
- Effects of prostacyclin (PGX) on cyclic AMP concentrations in human plateletsProstaglandins, 1977
- Modulation of human platelet adenylate cyclase by prostacyclin (PGX)Prostaglandins, 1977
- An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregationNature, 1976
- A highly sensitive adenylate cyclase assayAnalytical Biochemistry, 1974